Skip to content
DataLookout
Menu

NCT07949656

Anisodine Hydrobromide for Acute Vertebrobasilar Artery Occlusion Undergoing Endovascular Treatment: A Phase Ib Dose-Escalation Study

StatusNot Yet Recruiting
PhasePhase 1
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 1 version: 1 with changes below.

  1. Study First Submitted

Endpoints

Primary

Occurrence of Predefined Safety Events Within 8 Days
Timeframe: Within 8 days after the first administration

Secondary (8)

Early Neurological Deterioration
Infarct Volume
Functional Outcome (Modified Rankin Scale)
Incidence of Symptomatic Intracranial Hemorrhage
Incidence of Any Intracranial Hemorrhage
Show 3 moreShow less
Incidence of Study Drug-Related Adverse Events
Incidence of Study Drug-Related Serious Adverse Events
All-Cause Mortality

Arms and interventions

Anisodine Hydrobromide 1.0 mgExperimental

Participants receive anisodine hydrobromide 1.0 mg per dose intravenously twice daily for 7 consecutive days in addition to standard endovascular therapy. The first dose is initiated before vascular recanalization; however, administration of the study drug must not delay EVT or other standard endovascular procedures. The study drug is diluted in 0.9% sodium chloride solution and infused over approximately 60 minutes.

Anisodine Hydrobromide 1.5 mgExperimental

Participants receive anisodine hydrobromide 1.5 mg per dose intravenously twice daily for 7 consecutive days in addition to standard endovascular therapy. The first dose is initiated before vascular recanalization; however, administration of the study drug must not delay EVT or other standard endovascular procedures. The study drug is diluted in 0.9% sodium chloride solution and infused over approximately 60 minutes.

Anisodine Hydrobromide 2.0 mgExperimental

Participants receive anisodine hydrobromide 2.0 mg per dose intravenously twice daily for 7 consecutive days in addition to standard endovascular therapy. The first dose is initiated before vascular recanalization; however, administration of the study drug must not delay EVT or other standard endovascular procedures. The study drug is diluted in 0.9% sodium chloride solution and infused over approximately 60 minutes.

Anisodine Hydrobromide 2.5 mgExperimental

Participants receive anisodine hydrobromide 2.5 mg per dose intravenously twice daily for 7 consecutive days in addition to standard endovascular therapy. The first dose is initiated before vascular recanalization; however, administration of the study drug must not delay EVT or other standard endovascular procedures. The study drug is diluted in 0.9% sodium chloride solution and infused over approximately 60 minutes.

Drugs: Anisodine Hydrobromide